Credit Suisse Keeps Their Buy Rating on Aetna Inc

By Carrie Williams

Credit Suisse analyst Scott Fidel maintained a Buy rating on Aetna Inc (NYSE: AET) on May 12 and set a price target of $155. The company’s shares opened today at $141.86, close to its 52-week high of $144.87.

According to, Fidel is a 4-star analyst with an average return of 9.7% and a 68.0% success rate. Fidel covers the Healthcare sector, focusing on stocks such as WellCare Health Plans, Universal American, and Tivity Health Inc.

Currently, the analyst consensus on Aetna Inc is Moderate Buy and the average price target is $145.40, representing a 2.5% upside.

In a report issued on May 2, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $150 price target.

The company has a one year high of $144.87 and a one year low of $104.59. Currently, Aetna Inc has an average volume of 2.67M.

Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is negative on the stock. Earlier this month, Molly Joel Coye, a Director at AET sold 880 shares for a total of $125,118.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aetna, Inc. engages in the provision of traditional, voluntary, and consumer-directed health insurance products and related services. It operates through the following segments: Health Care, Group Insurance, and Large Case Pensions. The Health Care segment consists of medical, pharmacy benefit management services, dental, behavioral health, and vision plans offered on insured and employer-funded basis. The Group Insurance segment includes group life insurance and group disability products. The Large Case Pensions segment manages retirement products for tax-qualified pension plans. The company was founded by Eliphalet Adams Bulkeley in 1853 and is headquartered in Hartford, CT.